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Medullary thyroid cancers (MTC) are rare tumors of 
neuroendocrine origin that arise from parafollicular C 
cells which secrete a variety of peptides and hormones 
including calcitonin. As opposed to the more common 
papillary and follicular thyroid cancer subtypes, MTC 
represents a rare and under-characterized form of 
cancer, and can cause death if untreated (Taccaliti et 
al., 2011). 
MTC can be either sporadic, usually isolated to one
thyroid lobe, or familial, the latter of which is defined 
as the cancer syndrome known as Multiple Endocrine 
Neoplasia type 2 (MEN2) (Frank-Raue et al., 2010). 
MEN2 is the result of the autosomally dominant 
missense gain of function mutation in the RET 
(Rearranged during Transfection) proto-oncogene. 
MEN2 can be further subclassified into MEN2A, 
MEN2B and Familial Medullary Thyroid Carcinoma 
(FMTC). MEN2A is defined by the occurrence of 
medullary thyroid carcinoma (MTC), in conjunction 
with pheochromocytomas and primary 
hyperparathyroidism. MEN2B, is definied by the 
presence of MTC, pheochromocytomas, 
ganglioneuromatosis of the gastrointestinal tract, 
mucosal neuromas of the lips and tongue, and a 
Marfanoid body habitus (Frank-Raue et al., 2010). 
FMTC occurs when MTC is the only clinical feature, 
rarely with other endocrine neoplasias. Offspring of 
affected carriers of the RET mutation have a 50% 
chance of inheriting the mutation. 
Clinics and pathology 
Disease 
Medullary thyroid cancer 
Note 
Patients with sporadic MTC usually present with a neck 
mass while patients with hereditary MTCs that are 
diagnosed as mutation carriers should undergo 
prophylactic thyroidectomy before the onset of any 
symptoms. Sporadic MTC patients often present with 
metastasis to cervical and paratracheal lymph nodes. 
The diagnosis of MTC is based on history, physical 
exam, calcitonin and CEA levels, imaging, and fine 
needle aspiration biopsy. Every patient with diagnosed 
MTC should undergo genetic evaluation for the 
presence of the RET mutation. Histologically, tumors 
appear with hyperplastic parafollicular C-cells and 
predominantly present bilaterally (Taccaliti et al., 
2011). Sporadic MTC generally presents as a single 
tumor confined to one thyroid lobe. 
The prognosis of MTC is better than poorly 
differentiated, malignant anaplastic thyroid cancer, but 
worse than more differentiated and benign papillary 
and follicular thyroid cancer. Therefore, an early 
diagnosis is necessary for improving recurrence and
survival rates in these patients (Taccaliti et al., 2011). 
Phenotype / cell stem origin 
Their origin is characteristically from neural crest cells. 
These cells arise from the convergence between the 
dorsal ectoderm and the neural tube. Neural crest cells
eventually give rise to the chromaffin cells of the 
thyroid C cells in addition to chief cells of the extra-
adrenal paraganglia, and  
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A. Medullary thyroid carcinoma featuring groups of cells with polygonal to elongated cytoplasm, round-to-oval nuclei with indistinct 
nucleoli. Note amyloid deposition in the stroma (H&E, x200). B. Strong immunopositivity for calcitonin in all tumor cells 
(immunoperoxidase staining, x200). 
 
those of the adrenal medulla. The endocrine tumors that 
arise from thyroid C cells at earlier stages of 
differentiation generate medullary thyroid carcinomas. 
RET gene testing of germline deoxyribonucleic acid 
(DNA) at the chromosomal region 10q11.2 must be 
performed in patients with family history of MTC. This 
test will identify hereditary MTC among 95% or more 
of individuals with MEN2A and MEN2B. Additionally, 
88% of individuals with FMTC are identifiable through 
RET testing (National Cancer Institute, National 
Institutes of Health, www.cancer.gov). 
Etiology 
Medullary thyroid cancer can be classified into 4 types: 
1) Sporadic 
2) Hereditary MEN2A 
3) Hereditary MEN2B 
4) Hereditary familial medullary thyroid cancer 
(FMTC) 
Epidemiology 
In the United States, thyroid cancer comprises 3% of 
new malignancies occurring every year. Approximately 
56460 of projected cases of the cancer will be 
diagnosed of which 1780 will result in death. MTC 
accounts for approximately 5-8% of all thyroid cancer. 
About 20-25% of MTC cases are the result of MEN2 
syndromes. However, most MTC reports are sporadic 
(National Cancer Institute, National Institutes of 
Health, www.cancer.gov). Among those, 56% occur as 
MEN2A, 9% as MEN2B, and 35% as FMTC (Frank-
Raue et al., 2010). 
MTC typically occur in third or fourth decade of life in 
MEN2A patients. MEN2B patients develop the disease 
usually in early childhood. Onset of disease in FMTC 
patients generally occurs in middle age. 
 
Clinics 
Sporadic MTC generally presents as a single tumor 
confined to one thyroid lobe while familial presents 
often bilaterally. Most MTC patients will present with 
neck mass and may complain of hoarseness, dysphagia, 
and/or difficulty swallowing and breathing. MTC 
patients often present with metastasis to cervical and
paratracheal lymph nodes. Distant metastatic sites of 
MTC may include lung, liver, and bones, and more 
rarely to the brain and skin. Disseminated disease may
cause symptoms of weight loss, lethargy, and bone 
pain. MTC patients often present with diarrhea due to 
an increased secretion of an intestinal electrolyte which 
occurs secondary to high plasma calcitonin levels. 
Flushing similar to that present in carcinoid tumor 
patients often occurs to a similar degree, as a result of 
the hypersecretion of calcitonin and related gene 
products. 
Pathology 
Histologically, tumors appear with hyperplastic 
parafollicular C-cells and predominantly present 
bilaterally in familial cases. MTC may be preceded by 
C-cell hyperplasia (CCH). However, CCH is a 
relatively common occurence in middle-aged adults 
(LiVolsi, 1997; Nose, 2011). 
Treatment 
In sporadic cases total thyroidectomy and central 
lymph node dissection should be performed following 
the diagnosis of MTC. Lateral lymph node dissection 
should be added when lateral lymph node involvement 
is identified. For patients who are known carriers of the 
RET mutation surgery should be offered prior to the
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recommend surgery at a certain age according to each
mutation and the associated aggressive disease nature. 
Operating later during adulthood increases the 
likelihood of local recurrences and distant metastasi  
(Brandi et al., 2001). 
Surgery for recurrent disease should be considered if 
cure is possible and there are no distant metastases. 
Following the first surgery, the decision to reoperat  
can be determined based on the extent of metastatic 
disease. If distant metastases are found, surgery may 
only be indicated if the patient presents with 
irretraceable symptoms. These cases may benefit from
tumor debulking (Brandi et al., 2001). 
For patients with metastatic MTC for which surgery 
offers no cure, there are unfortunately few 
chemotherapeutic options. Furthermore, MTC responds 
poorly to radiotherapy regimens. However, some 
patients with substantial burdens of metastatic MTC 
can remain asymptomatic and live for many years 
(Taccaliti et al., 2011). 
Prognosis 
The prognosis of MTC is worse than that of follicular 
and papillary thyroid cancer. Its natural history varies 
anywhere from latent lingering disease after surgery to 
aggressive disease and even death related to metastatic 
thyroid tumor burden. Patients with hereditary MTC 
that undergo prophylactic surgery have an excellent 
prognosis and are virtually cured (Raue, 1998). For
patients with MTC the 10-year survival rates vary from 
about 61% to 76% (Raue, 1998; Kebebew et al., 2000; 
Roman et al., 2006). MTC is often diagnosed using 
screens for calcitonin and carcinoembryonic antigen 
(CEA). Factors such as patients' age, sex, calcitonin 
doubling time in addition to tumor volume and lymph 
node dissemination will dictate stage and prognoses. 
Genes involved and proteins 




The RET (REarranged during Transfection) gene is a 
member of the proto-oncogene cadherin superfamily of 
Receptor Tyrosine Kinases which regulate such 
processes as growth and differentiation of neural crest 
cells, from which MTCs derive. When cytogenetically 
rearranged, it can undergo oncogenic activation. 
Genetic diagnosis is crucial in order to differentiate 
familiar from sporadic MTC. It must be performed 
early on when a family history is remarkable (Frank-
Raue et al., 2010). 






NKX2-1 gene encodes proteins involved in the budding 
and migration of the midline thyroid anlage. Its 
translated protein serves to bind to the thyroglobulin 
promoter which leads to the downstream expression of 
thyroid-specific genes and morphogenic processes. 
This protein is regarded as a thyroid-specific 
transcription factor. Mutations and deletions in this 
gene may be associated with sporadic medullary 
thyroid cancer (Westerlund et al., 2008). 
BRAF (v-raf murine sarcoma viral 




BRAF encodes a member of the raf/mil family of 
serine/threonine protein kinases and functions as akey 
regulator in the ERK signalling. This pathway is 
involved cell division differentiation, and bioactivi y. 
Gene mutations have been associated with sporadic 
medullary thyroid carcinoma (Nikiforova et al., 2003). 





PTEN encodes a tumor suppressor that is mutated in 
many cancers, and encodes a phosphatidylinositol-
3,4,5-trisphosphate 3-phosphatase. It negatively 
regulates intracellular levels of phosphatidylinosit l-
3,4,5-trisphosphate in the AKT/PKB signaling pathway 
(Nose, 2011). 
HRAS (v-Ha-ras Harvey rat sarcoma 




HRAS encodes an oncogene which is a member of the 
Ras family. These genes are related to the transforming 
genes of mammalian sarcoma retroviruses and their 
products behave as GTPase proteins. Therefore, HRAS 
mutations can lead to a variety of cancers including 
MTC. Analysis of single nucleotide polymorphisms 
(SNPs) revealed SNPs in HRAS among patient 
haplotypes have been shown to be associated with 
sporadic MTC. (Ruiz-Llorente et al., 2007; Barbieri, 
2012). 




This gene encodes p53, involved with apoptosis, cell  
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cycle arrest, DNA repair and metabolic processes. P53 
binds DNA to induce expression of downstream genes 
that inhibit growth, thus making it a tumor suppressor. 
p53 mutants have been shown to bind poorly to DNA, 
thus repressing tumor suppressor activity. Regression 
analysis studies of TP53 genotype mutations among 
patients in recent studies have shown to lead to 
interited increased risk of sporadic MTC (Joao Bugalho 
et al., 2008; Barbieri, 2012). 





VEGFA encodes a growth factor of which mutations 
can cause proliferative and nonproliferative retinopathy 
in diabetic patients. Multiple isoforms have been 
identified due to upstream translation initiation site  of 
the AUG start codon. Furthermore, splice variants have 
also been identified of different isoforms, including 
ones either freely secreted or cell-associated. Studies 
have shown that VEGF expression in thyroid 
carcinoma correlated with the tumor type and TNM 
stage. This may suggest that VEGF plays a role in 
angiogenesis and metastasis of thyroid cancer (Ji et al., 
2012). 




PTTG1 encodes a homolog of securin proteins, which 
functions to block the separation of sister chromatids 
during anaphase until activation of the anaphase-
promoting complex (APC) which it binds to upon APC 
activation. This gene is highly expressed in a variety of 
tumors and is mainly a cytosolic protein while partially 
localized in the nucleus. Levels of PTTG1 have been 
shown to correlate with MTC aggressiveness among 
other cancers. Silencing PTTG1 has been shown to 
reduce MTC cell proliferation. This supports the 
hypothesis that PTTG1 might have an important role in 
MTC cell proliferation and metastasis and may be a 
therapeutic target (Zatelli et al., 2010). 




ESR2 encodes an estrogen receptor, a nuclear receptor 
transcription factor containing a DNA binding domain 
on the N-terminus. When 17beta-estradiol binds to 
ESR2, the complex forms either a homodimer or 
heterodimer with ESR1. In normal physiology, ESR1 
plays a role in sexual development reproduction as well 
as bone and tissue development, but may be mutated in 
a variety of cancers. Furthermore, alternative splice 
variants exist.  
ESR2, but not ESR1, is present in thyroid tissue, but 
there are no notable associations between ESR2 
expression and differentiation between benign and 
malignant MTCs (Vaiman et al., 2010). 





This is an N-ras oncogene encoding a membrane 
protein that shuttles between the Golgi apparatus and 
the plasma membrane. This shuttling is regulated 
through palmitoylation and depalmitoylation by the 
ZDHHC9-GOLGA7 complex. The encoded protein, 
which has intrinsic GTPase activity, is activated by a 
guanine nucleotide-exchange factor and inactivated by 
a GTPase activating protein. Mutations in this gene 
have been associated with somatic rectal cancer, 
follicular thyroid cancer, autoimmune 
lymphoproliferative syndrome, Noonan syndrome, and 
juvenile myelomonocytic leukemia (Schulten et al., 
2011; Almeida and Hoff, 2012). 





EGFR encodes a transmembrane glycoprotein receptor 
with kinase activity and is a member of the epidermal 
growth factor family. Binding of the epidermal growth 
factor to the EGFR induces receptor dimerization and
tyrosine autophosphorylation, in turn causing cell 
growth and proliferation. EGFR gene mutations have 
been shown to cause lung cancer. Alternatively spliced 
transcript variants encoding different isoforms have 
been described. Targeting EGFR through small 
molecule inhibitors has been shown to be useful in 
treating various cancers including MTC. Recently, 
vandetanib (ZD6474), EGFR inhibitor, was approved 
for treating progressive and symptomatic MTC 
(Almeida and Hoff, 2012). 
NFKB1 (nuclear factor of kappa light 




This 105 kD protein may undergo 26S proteasome 
processing to produce a 50 kD protein, which is a DNA 
binding subunit of the NF-kappa-B (NFKB) protein 
complex. This serves as a transcription regulator 
activated by various cell stresses including cytokines, 
free radicals, UV radiation, and bacterial or viral  
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products. Upon activation, NFKB enters the nucleus 
where it induces gene expression in a variety of cell 
survival and immune related functions. Super 
activation of NFKB has been shown to cause 
inflammatory diseases, irregular immune cell 
development or delayed cell growth. Recently, NFKB 
has been shown to play an important role in thyroid 
cancer. It may play a critical role in controlling thyroid 
cancer cell proliferation and their anti-apoptotic 
signaling pathways cells (Gallel et al., 2008; Pacifico 
and Leonardi, 2010). 
STAT3 (signal transducer and activator 





The STAT3 gene encodes a protein which is a member 
of the STAT protein family. These proteins are 
phosphorylated by the receptor associated kinases in 
response to growth factors and cytokine stimuli. 
STAT3 then translocates to the nucleus as a complexes, 
in order to activate the transcription of downstream 
genes involved with growth and apoptosis. Three 
alternatively spliced transcript variants producing 
different isoforms have been identified. Recent studies 
have demonstrated that FMTC-RET mutants activate 
the Ras/ERK1/2 pathway, upstream of the STAT3 
Ser727 pathway. This may play an important role in 
thyroid cancer oncogenic transformation (Plaza-
Menacho et al., 2007). 
MMP2 (matrix metallopeptidase 2 
(gelatinase A, 72kDa gelatinase, 72kDa 




Matrix metalloproteinase (MMP) are involved in the 
disintegration of the extracellular matrix in normal 
physiologic processes such as reproduction and tissue 
remodeling, embryonic development, would healing, as 
well as in cancer metastasis. MMP2 degrades type IV 
collagen, which plays a structural role in basement 
membranes. Two transcript variants encoding different 
isoforms have been found for this gene. A recent study 
assessing a panel of MTC cancer specimens found that 
expression of MMP2 could be used as a prognostic tool 
(Cavalheiro et al., 2008). 




Notch1 is a member of the Notch transmembrane 
protein family (Notch1-4) which possesses an 
extracellular domain of epidermal growth factor-like 
(EGF) repeats, and an intracellular domain containing 
different domain types. Notch signaling is initiated 
intercellularly following physical interaction between 
the ligands (delta serrate) on adjacent cells, and is 
evolutionarily conserved. This protein is cleaved in the 
trans-Golgi network, and presented on the cell surface 
as a heterodimer. This protein functions as a receptor 
for membrane bound ligands, and may play multiple 
roles during development. Notch1 has been identified 
as a tumor suppressor in MTC in addition to other 
neuroendocrine tumors such as carcinoids. In MTC 
cells, Notch1 is expressed at very low to absent levels; 
however, upregulating NOTCH1 expression reduces 
MTC cell proliferation and phenotypic expression 
(Kunnimalaiyaan et al., 2006). 




Glial cell line-derived neurotrophic factor (GDNF) is a 
glycosylphosphatidylinositol(GPI)-linked receptor on 
the cell surface and plays key roles in differentiation 
and survival of neurons. It is involved in regulation of 
the RET tyrosine kinase activity. Multiple alternatively 
spliced transcript variants have been described for 
various GFRA1 isoforms. Furthermore, germline 
polymorphisms in RET and GFRA1 and correlations 
with genetic predispositions to developing sporadic 
MTC have been described. Modulating these 
polymorphisms have been described to affect clinical 
features of the disease as well (Severskaia et al., 2006). 
KRAS (v-Ki-ras2 Kirsten rat sarcoma 




Kirsten RAS oncogene homolog is a small GTPase and 
member of the mammalian RAS gene family. 
Mutations can be caused by an amino acid substitution 
causing oncogenic activation in various malignancies.  
Alternative splicing leads variants of two isoforms have 
been described. Mutation screening of KRAS may be 
warranted but still inconclusive (Schulten et al., 2011). 





MTOR serves as a target of FKBP12-rapamycin 
complex which enables the immunosuppression and 
cell cycle inhibition. It belongs to a family of 
phosphatidylinositol kinase-related kinases which 
regulate cell processes such as growth and survival in 
response to DNA damage, free radical damage and 
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nutrient deprivation. MTOR signaling is aberrantly 
activated in MTC especially in tissues harboring 
germline RET mutations MTC (Rapa et al., 2011). 
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